Psilocybin and TNF-Alpha: Systemic Anti-Inflammatory Evidence

Psilocybin & Neuroinflammation

2023 first placebo-controlled human trial

Mason and colleagues published the first placebo-controlled study showing psilocybin acutely lowers the pro-inflammatory cytokine TNF-alpha and produces persisting immune changes in healthy volunteers, establishing that psilocybin's effects reach well beyond the brain.

Mason et al., Brain, Behavior, and Immunity, 2023

TNF-alpha

the pro-inflammatory cytokine most consistently elevated in treatment-resistant depression

Mason 2023

placebo-controlled trial: psilocybin acutely reduced TNF-alpha; IL-6 and CRP were persistently lower at 7 days

AhR

a signaling route Laabi 2025 found is required for psilocin's neuroplasticity (BDNF) effect, alongside serotonergic anti-inflammatory signaling

Mason et al., Brain, Behavior, and Immunity, 2023

View as image ↗

The dominant story of psilocybin's mechanism focuses on serotonin: the drug binds 5-HT2A receptors, disrupts the brain's default mode network, and enables new patterns of thinking and emotional processing. That story is well-supported. But a separate line of evidence has been accumulating quietly, suggesting psilocybin also does something to the immune system. Specifically, it appears to affect the inflammatory signaling proteins called cytokines, including TNF-alpha (tumor necrosis factor-alpha), the protein most consistently elevated in patients with treatment-resistant depression.

In 2023, a placebo-controlled human trial found that psilocybin acutely reduced circulating TNF-alpha, and that a week later two other inflammatory markers, IL-6 and C-reactive protein, were still lower than before.^[2] A separate 2024 analysis that pooled blood samples across several trials found a more mixed picture, with no measurable TNF-alpha change and only a transient rise in a different cytokine.^[1] This evidence is early-stage, but the question it raises is significant: if psilocybin reduces inflammatory signaling, and if that inflammation is partly driving depression, does the anti-inflammatory effect contribute to why the drug works? For broader context on psilocybin's neuroscience, see Psilocybin and the Default Mode Network: How It Quiets the Ego.

TNF-Alpha: The Inflammatory Marker Most Linked to Depression Severity

TNF-alpha is a signaling protein released by immune cells. It's one of the primary messengers the immune system uses to trigger and maintain inflammation. During infection or injury, TNF-alpha production is protective. When chronically elevated without an acute threat, it becomes a problem.

Meta-analyses of inflammatory markers in depression have consistently identified TNF-alpha elevation as one of the most reproducible biological findings in patients with major depression. The association is particularly strong in treatment-resistant cases, the patients who don't improve with multiple antidepressants, where inflammatory dysregulation appears to be a defining feature rather than an incidental finding.

This matters for psilocybin research for a specific reason. If a subset of depression is driven or maintained by chronic low-grade inflammation, and if standard antidepressants don't substantially target that inflammation, then a compound that does modulate inflammation could work through a mechanism entirely distinct from serotonin reuptake.

For context on psilocybin's effects on neuroinflammation in the brain specifically, see Psilocybin and Neuroinflammation: Anti-Inflammatory Brain Effects.

How Systemic Inflammation Gets Into the Brain and Disrupts Mood

TNF-alpha is produced peripherally, in blood, fat tissue, and organs, but its effects on the brain are direct. The blood-brain barrier, the protective lining that separates the brain's blood supply from brain tissue, was once thought to block TNF-alpha reliably. It doesn't.

At elevated concentrations, TNF-alpha crosses the blood-brain barrier through several routes: active transport mechanisms, passage through areas of the barrier where it's naturally more permeable, and indirect effects via cells lining the barrier itself. Once inside the brain, TNF-alpha has documented effects on serotonin synthesis, reuptake, and receptor expression: the exact systems that antidepressants target.

This creates a scenario where peripheral inflammation can undermine serotonin-based treatments from the outside. A patient's brain may have adequate antidepressant coverage at the synaptic level while an inflammatory signal from the blood keeps disrupting the very system being treated.

TNF-alpha in the brain also activates microglia, the brain's resident immune cells. Activated microglia release their own pro-inflammatory signals, creating a feedback loop in which peripheral inflammation triggers central inflammation, and central inflammation degrades the neural environment that mood regulation depends on. For a deeper look at psilocybin's effects on microglia specifically, see Psilocybin and Microglial Modulation: Anti-Inflammatory Effects in the Brain.

Mason 2023: The Placebo-Controlled Trial That Directly Measured TNF-Alpha

The strongest human evidence comes from Mason and colleagues in Brain, Behavior, and Immunity (2023).^[2] The design was placebo-controlled and parallel-group: 60 healthy volunteers received either placebo or 0.17 mg/kg psilocybin, and blood was drawn to measure immune status acutely and again seven days later.

The results were specific rather than generic. Psilocybin immediately reduced concentrations of TNF-alpha, while three other inflammatory markers (IL-1-beta, IL-6, and C-reactive protein) were unchanged in the acute window. Seven days later the pattern had shifted: TNF-alpha had returned to baseline, but IL-6 and C-reactive protein were now persistently reduced in the psilocybin group. In other words, the anti-inflammatory signature moved over time, from an acute drop in TNF-alpha to a lingering drop in IL-6 and CRP.

Anchor Study

Mason et al. (2023) · Brain, Behavior, and Immunity

Population

60 healthy volunteers

Intervention

0.17 mg/kg psilocybin

Comparator

Placebo (parallel-group)

Finding

Psilocybin immediately reduced TNF-alpha (IL-1-beta, IL-6, and CRP unchanged acutely). Seven days later TNF-alpha had returned to baseline while IL-6 and CRP were persistently reduced. Larger seven-day IL-6/CRP reductions correlated with more persisting positive mood and social effects; the acute TNF-alpha drop tracked lower hippocampal glutamate.

positive Healthy volunteers, not depressed patients, and the mood link is a correlation, not proof of cause.

Mason et al., Brain, Behavior, and Immunity, 2023 (RTHM-01747)

Two further details make this study the anchor of the anti-inflammatory case. First, the acute reduction in TNF-alpha was linked to neurometabolic activity: participants with larger TNF-alpha drops showed lower concentrations of glutamate in the hippocampus, connecting the peripheral immune change to a brain measurement. Second, and most relevant to the therapeutic question, participants whose IL-6 and CRP fell more at seven days reported more persisting positive changes in mood and social behavior.

That second finding is the closest thing in the current literature to a bridge between psilocybin's immune effects and its psychological effects, but it must be read carefully. It is a correlation within a sample of healthy volunteers, not a demonstration that lowering inflammation caused the mood change, and not a study in depressed patients. It is a strong lead, not a settled mechanism.

DiRenzo 2024: A Mixed Human Result That Complicates the Story

If Mason 2023 is the encouraging data point, DiRenzo and colleagues (2024), published in Psychedelic Medicine, is the necessary counterweight.^[1] This analysis pooled serum from 91 participants across three prior randomized controlled trials, spanning very different populations: people with no known health problems and a long-term meditation practice, people with depression, and people with anxiety and cancer.

The result was largely null. In the pooled models, the only statistically significant change was a transient increase in IL-8 within one week of psilocybin. There were no significant changes in TNF-alpha or IL-6. At time points four weeks or later, there were no changes at all, and when the trials were analyzed individually rather than pooled, no cytokine changes reached significance at any time point.

This matters for calibration. DiRenzo 2024 did not replicate a TNF-alpha effect, and the one change it did detect, a short-lived rise in IL-8, points in the pro-inflammatory rather than the anti-inflammatory direction. The authors themselves framed it as preliminary, noting only that peripheral cytokine production is "possibly altered" by psilocybin and that the effect was not consistent across patient populations. Taken together with Mason 2023, the honest reading is that psilocybin can move human cytokine levels, but the size, direction, and durability of that movement are not yet consistent from study to study.

What the Cellular Evidence Shows: Psilocin's Direct Anti-Inflammatory Action

The human data establish that psilocybin affects the immune system; the cell studies begin to explain how, and they add an important nuance. A 2024 in vitro study by Laabi and colleagues examined psilocybin and psilocin (the drug's active metabolite) in cultured macrophages, a type of immune cell.^[3]

The finding was context-dependent, which the earlier framing of this topic often glosses over. In resting macrophages, both psilocybin and psilocin actually increased TNF-alpha. It was only in activated macrophages, cells that had been stimulated to mimic an ongoing inflammatory state, that an anti-inflammatory effect appeared: there, psilocin (more than psilocybin) reduced TNF-alpha and raised the anti-inflammatory cytokine IL-10. The authors' conclusion was specific: psilocin, not psilocybin, exerts anti-inflammatory effects on classically activated macrophages.

That specificity is mechanistically important. It suggests the anti-inflammatory action is carried largely by the metabolite the body converts psilocybin into, and that it shows up preferentially where inflammation is already switched on, which is exactly the context that matters for inflammation-associated depression. It also means blanket statements that "psilocybin is anti-inflammatory" overstate what the cell data show.

A Second Signaling Route: How AhR Fits Alongside Serotonin

The most recent finding in this research area comes from Laabi and colleagues in 2025, extending the in vitro work into microglia, the brain's resident immune cells.^[4]

In LPS-activated microglia, psilocybin and psilocin suppressed TNF-alpha and increased BDNF, a protein central to neuroplasticity. The study then used selective antagonists to work out which receptors did what, and the answer refines a claim that is often stated too loosely. The TNF-alpha suppression was mediated by serotonergic receptors (5-HT2A, 5-HT2B, 5-HT7) and TrkB signaling. The AhR, by contrast, was required for the BDNF (neuroplasticity) effect, specifically psilocin's, and was not required for TNF-alpha suppression.

So the accurate picture is not "AhR is a second anti-inflammatory pathway." It is that psilocybin's anti-inflammatory action in these cells runs mainly through serotonergic and TrkB signaling, while the AhR runs alongside it as a route to neuroplasticity. The two effects, calming inflammation and supporting neuroplasticity, appear to be driven by overlapping but distinguishable signaling networks operating at the same time. (The study also found that IL-10 rose when serotonergic, TrkB, or AhR signaling was blocked, hinting at compensatory anti-inflammatory pathways the cell can fall back on.) For more on psilocybin's neuroplasticity effects, see Psilocybin and Neuroplasticity: Rewiring the Brain and How Psilocybin Grows New Dendritic Spines.

What Each Study Actually Found

The TNF-α Evidence Is Real, Early, and Not Uniform

Four studies are usually cited for psilocybin’s anti-inflammatory signal. Read them side by side and the picture is more honest than a headline: one placebo-controlled human trial lowered TNF-α, a second human analysis found no TNF-α change at all, and the cell studies show the effect belongs mostly to psilocin and only in activated immune cells.

[2]Mason 2023Human · placebo-controlled

↓TNF-α ↓ acute

60 healthy volunteers, 0.17 mg/kg. Psilocybin acutely reduced TNF-α; seven days later IL-6 and CRP were persistently reduced, and larger drops tracked more persisting positive mood.

Strongest human signal — but healthy volunteers, and the mood link is correlational

[1]DiRenzo 2024Human · pooled RCT sera

—TNF-α — no change

91 participants pooled across 3 trials, mixed populations. Only significant change was a transient IL-8 increase at ≤1 week. No TNF-α or IL-6 change; nothing at ≥4 weeks; null in per-study models.

A cautionary null — did not replicate a TNF-α effect

[3]Laabi 2024In vitro · murine macrophages

↕TNF-α ↓ only if activated

Context-dependent. In resting cells both psilocybin and psilocin raised TNF-α; in LPS-activated cells psilocin (not psilocybin) lowered TNF-α and raised anti-inflammatory IL-10.

The anti-inflammatory effect is psilocin’s, and only on activated cells

[4]Laabi 2025In vitro · microglia

↓TNF-α ↓ (serotonergic/TrkB)

Psilocybin and psilocin suppressed TNF-α and raised BDNF. TNF-α suppression ran through serotonergic + TrkB signaling; AhR was required for the BDNF (neuroplasticity) effect, not for TNF-α suppression.

Cleanest mechanistic TNF-α suppression — but in a dish, not a patient

Direction of effect is taken directly from each study’s reported results. “In vitro” means cells in culture, not people. No study here measured inflammatory markers and clinical depression outcomes together in patients, so none of them shows that lowering TNF-α is why psilocybin helps mood.

Evidence synthesis; findings from refs [1][2][3][4] (see references)

What This Evidence Does and Doesn't Tell Us

The research summarized here establishes several things with reasonable confidence. In a placebo-controlled human trial, psilocybin acutely lowered TNF-alpha and persistingly lowered IL-6 and CRP, with the persisting reductions correlating with mood and social improvement (Mason 2023). In cultured immune and microglial cells, the metabolite psilocin lowers TNF-alpha in activated cells and raises anti-inflammatory IL-10, working through serotonergic and TrkB signaling, alongside an AhR-dependent neuroplasticity effect (Laabi 2024 and 2025).

What the evidence does not establish is equally important. The human cytokine data are not yet consistent: DiRenzo 2024, pooling 91 participants across three trials, found no TNF-alpha change and only a transient IL-8 increase. None of the human work measured immune markers and depression outcomes together in patients, so the correlation Mason found (in healthy volunteers) is suggestive, not causal. The cellular studies, however clean, are in vitro, and the anti-inflammatory effect in them belonged largely to psilocin and appeared mainly in already-activated cells.

Evidence Review

1. Cell studiescompleted

   Laabi 2024 (macrophages) and 2025 (microglia): psilocin lowers TNF-alpha in activated cells via serotonergic/TrkB signaling; AhR drives a parallel BDNF effect.

2. Animal studiesmissing

   No published study directly tests whether psilocybin's TNF-alpha reduction changes depression-like behavior in animals.

3. Small human trialscurrent

   Mason 2023 (placebo-controlled, healthy volunteers) found acute TNF-alpha and persisting IL-6/CRP reductions; DiRenzo 2024 (pooled sera) found no TNF-alpha change. Mixed.

4. Large RCT in patientsmissing

   No adequately powered trial measures inflammatory markers and clinical depression outcomes together to test mediation.

5. Meta-analysismissing

   Too few and too heterogeneous studies to pool.

The mechanism is plausible and partly demonstrated in cells and in one placebo-controlled trial, but the human evidence is mixed and no study yet shows that lowering TNF-alpha is why psilocybin improves mood.

Mason 2023 (RTHM-01747); DiRenzo 2024 (RTHM-01881); Laabi 2024 (RTHM-01922); Laabi 2025 (RTHM-02121)

The causal question of whether reducing TNF-alpha or modulating cytokine profiles contributes to clinical improvement in depressed patients has not been answered. That requires a study design that measures both immune and clinical outcomes simultaneously, in patients, with enough statistical power to test mediation. Those studies are not yet published.

The honest assessment: psilocybin affects the immune system in ways that are pharmacologically interesting and clinically plausible as a partial mechanism, and the placebo-controlled Mason data give that idea real weight. But the human evidence is mixed, the strongest positive signal is a correlation in healthy volunteers, and the mechanistic detail comes from cells in culture. The connection to clinical outcomes is currently a well-supported hypothesis, not a demonstrated causal chain. For the broader argument about how this anti-inflammatory evidence might fit into a more complete model of psilocybin's mechanism, see The Neuroimmune Connection: How Psilocybin's Anti-Inflammatory Effects May Drive Healing.

Legal & Safety

Moderate

This is research, not a treatment protocol

Concern

Psilocybin is a Schedule I controlled substance in the United States. The immune findings described here come from controlled research settings and in vitro models; none of them establishes psilocybin as a treatment for inflammation or for depression.

What the research says

The anti-inflammatory data are early, partly mixed, and largely mechanistic. No dose, formulation, or protocol for using psilocybin to lower inflammation has been clinically validated, and possession and use are illegal in most jurisdictions.

Particularly relevant for: Anyone considering psilocybin for depression or inflammation

What to do

Do not self-treat. Psilocybin for depression is currently available only through approved clinical trials and, in a small number of jurisdictions, supervised programs. Discuss depression treatment with a licensed clinician.

Not medical advice.

The Bottom Line

TNF-alpha elevation is a well-replicated finding in treatment-resistant depression, and psilocybin appears able to modulate it, though the human evidence is not yet consistent. In the placebo-controlled Mason 2023 trial, psilocybin acutely reduced TNF-alpha and persistingly reduced IL-6 and CRP, with the seven-day reductions correlating with lasting positive mood in healthy volunteers. DiRenzo 2024, pooling 91 participants across three trials, found no TNF-alpha change and only a transient IL-8 increase, a cautionary counterweight. Cell studies show the anti-inflammatory action belongs mainly to the metabolite psilocin and appears in activated cells, running through serotonergic and TrkB signaling; the AhR pathway was required for a parallel neuroplasticity (BDNF) effect rather than for TNF-alpha suppression itself (Laabi 2024 and 2025). Whether anti-inflammatory action contributes causally to psilocybin's antidepressant effects is not yet established. Psilocybin is a Schedule I substance in the United States; the studies described here are research findings only.

Frequently Asked Questions

Does psilocybin lower TNF-alpha?

In the placebo-controlled Mason 2023 trial, psilocybin acutely reduced circulating TNF-alpha in healthy volunteers, while other markers (IL-1-beta, IL-6, CRP) were unchanged in that acute window. So there is direct human evidence for a short-term TNF-alpha reduction. However, a larger pooled analysis (DiRenzo 2024, 91 participants across three trials) found no TNF-alpha change and only a transient increase in a different cytokine, IL-8. The overall picture is that psilocybin can lower TNF-alpha acutely under some conditions, but the human data are not yet consistent, and no trial has tested this specifically in depressed patients as a primary endpoint.

What is TNF-alpha and why does it matter for depression?

TNF-alpha (tumor necrosis factor-alpha) is a signaling protein released by immune cells to trigger and maintain inflammation. It is one of the inflammatory markers most consistently elevated in patients with major depression, particularly treatment-resistant cases. At elevated concentrations, TNF-alpha crosses the blood-brain barrier and can disrupt serotonin synthesis and receptor expression, which may help explain why serotonin-targeting antidepressants are less effective in patients with a high inflammatory burden. Reducing TNF-alpha is therefore a clinically plausible mechanism for improving antidepressant response, though it remains an unproven one.

How does psilocybin affect cytokines?

The human evidence is mixed. Mason 2023 found an acute reduction in TNF-alpha and, seven days later, persistingly reduced IL-6 and CRP; DiRenzo 2024 found no TNF-alpha or IL-6 change and only a transient IL-8 increase. Cell studies suggest the anti-inflammatory action is carried mainly by psilocin (the active metabolite) and appears in already-activated immune cells, working through serotonergic (5-HT2) and TrkB signaling. A separate route, the aryl hydrocarbon receptor (AhR), was required in microglia for psilocin's neuroplasticity (BDNF) effect rather than for its TNF-alpha suppression. Whether any of this reaches a clinically meaningful magnitude in depressed patients is not yet established.

Is there evidence psilocybin has systemic anti-inflammatory effects?

Yes, but it is early and not uniform. Mason and colleagues (2023) ran a placebo-controlled human trial and found psilocybin acutely lowered TNF-alpha and persistingly lowered IL-6 and CRP. Laabi and colleagues (2024 and 2025) identified cellular mechanisms through which psilocin produces anti-inflammatory effects in activated immune and microglial cells. Against this, DiRenzo and colleagues (2024) pooled 91 participants and found no TNF-alpha change and a transient pro-inflammatory IL-8 rise. So there is genuine evidence for systemic anti-inflammatory activity, alongside at least one human dataset that did not replicate it. Whether these effects contribute causally to clinical antidepressant outcomes is the unanswered next question.

Does psilocybin reduce inflammatory markers?

The direction of the strongest human evidence is toward reduction: Mason 2023 found acute TNF-alpha and persisting IL-6/CRP reductions in a placebo-controlled design, with the persisting reductions correlating with better mood in healthy volunteers. In vitro studies show psilocin can lower TNF-alpha and raise anti-inflammatory IL-10 in activated cells. But the evidence is not uniform: DiRenzo 2024 found no reduction in TNF-alpha or IL-6 and a transient rise in IL-8. None of these studies measured inflammatory markers in depressed patients specifically while also tracking clinical outcomes, so the evidence that psilocybin reliably reduces inflammation in the populations most likely to benefit is still accumulating.

Sources & References

1. 1RTHM-00874·DiRenzo, Dana et al. (2024). “Impact of Psilocybin on Peripheral Cytokine Production..” Psychedelic medicine (New Rochelle.Study breakdown →PubMed →↩
2. 2RTHM-00845·Mason, N L et al. (2023). “Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study..” Brain.Study breakdown →PubMed →↩
3. 3RTHM-00887·Laabi, Salma et al. (2024). “Deciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insights..” International immunopharmacology.Study breakdown →PubMed →↩
4. 4RTHM-00934·Laabi, Salma et al. (2025). “Psilocybin and psilocin regulate microglial immunomodulation and support neuroplasticity via serotonergic and AhR signaling..” International immunopharmacology.Study breakdown →PubMed →↩